Mike Hollan

The company states that no adverse events have been reported due to the contamination as of yet.

McCloskey discusses the steps that drug developers can take to ensure better CLD outcomes in 2024.

According to the university, new nanotech scaffolding can be used to support tissue growth.

Experts weigh in on recent trends regarding weight loss medication and how they expect those trends to evolve in the coming year.

The data was collected during the LEAP clinical program, developed in partnership with Merck.

As the technology becomes more ingrained within the Pharma industry’s processes, experts believe that regulation covering the use of AI is coming.

Investors may be attracted to precision medicine and gene therapy in the coming year due to a variety of reasons, including the treatments’ abilities to produce exact responses.

The device can produce AI-assisted readings.

The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.

The survey is part of the brand’s new marketing campaign.

While the industry as a whole still faces challenges, there are positive trends appearing for pharmaceutical and medical device companies.

Both companies are now under the Norstella umbrella.

The Healthcare Businesswomen’s Association will honor the recipient at an event later this year in New York City.

Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.

Pharm Exec spent the year speaking with some of the most interesting professionals from the life sciences industry.

As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023.

Pharma marketing teams had to deal with big changes in 2023.

As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.

These stories graced the cover of Pharmaceutical Executive this year

Data will continue to grow in importance in 2024.

Lisa Conte, founder, president, and CEO of Jaguar Health, discusses how a climb up Mount Kilimanjaro would vault her to her true career calling—and spark a decades-long quest to accelerate breakthroughs in plant-based pharmaceuticals and supportive care.

Experts gauge whether the needle is finally moving on the effective structuring of outcomes centered payment agreements—from operational, technology, and acceptance standpoints.

Continuous learning a vital skill for aspiring and established leaders alike.

Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.

Powley discusses his team’s recent patient journey mapping exercise and the impact it has had on RMMH.

Orne discusses the forces impacting the life sciences market and how companies are reacting.

Heidmann discusses the difficulties of enrolling patients in clinical trials and the ways these issues can be dealt with.

Leuchter discusses FDA’s new pilot program.

Smalley discusses her work with proactive signal detection.

Ho discusses how gamma-delta T cells can improve cancer treatments.